The field of immuno-oncology (IO) is consolidating its presence in most major types of cancer. Checkpoint modulation is the most valuable IO sector. Within 2021-2022, the next immuno-oncology breakthrough has not happened. High cost of therapy and need for personalized treatment using biomarkers remain as unmet needs.
Scope
- Overview of immuno-oncology including classification of therapy and technologies, regulatory and market access details, product & company profiles.
- Quotes from US- and 5EU-based key opinion leaders and payers.
- Key topics covered for IO in the 8MM include trends, value chain, market analysis, opportunities, challenges and unmet needs and high-value deals.
- Pipeline analysis: Comprehensive data split across different phases and indications, emerging novel trends under development, and analysis of the most promising late-stage pipeline drugs for each class of IO (Phase II - III).
- Analysis of the key dynamics of the IO market. Insightful review of the key industry drivers and challenges. Deals and R&D strategies covered in detail to highlight business opportunities.
- Robust analysis of high-prescriber survey conducted with 80 oncologists.
Reasons to Buy
- What impact will late-stage pipeline agents have on the market? Which class of IO drugs will have the highest peak sales, and why?
- What are the current unmet needs in IO, which pipeline agents or strategies are positioned to counter these unmet needs? What are the opportunities for R&D?
- How is the field of checkpoint modulation going to move forward? Which technologies are the most promising for combinations?
- What is the regulatory landscape for IO agents in the US, the 5EU Japan, and China?
- What is the current and future outlook of IO according to high prescribers?
Table of Contents
1. Preface
2. Executive Summary
3. Immuno-oncology Overview
4. Trends
5. Value Chain
6. Marketed Products
7. Pipeline Products
8. Market Analysis and Deals
9. Regulatory and Market Access
10. Opportunities, Challenges, and Unmet Needs
12. Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novartis
- Merck & Co
- Gilead
- Roche
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- Amgen
- Dendreon Pharmaceuticals
- Legend Biotech
- Johnson & Johnson
- Alphamab
- Genmab
- Regeneron
- Iovance Biotherapeutics
- Replimune
- Oncolytics
- Inovio
- VBI Vaccines
- Instil Bio
- Alaunos Therapeutics
- Jounce Therapeutics
- Arcus Biosciences
- Neoleukin Therapeutics
- Alkermes
- Oncosec
- Oncorus
